MEI Pharma, Inc.

As reported, MEI had $100.7 million in cash, cash equivalents and short-term investments at June 30, 2023, with no outstanding debt. Management said that cash is sufficient to fund operations for at least the next 12 months and through the reporting of clinical data readouts from the ongoing and planned voruciclib and ME-344 Phase 1/1b programs. No revenue, EPS, or gross margin figures were provided on the call. On guidance, the company expects voruciclib data in early 2024 and ME-344 data in the first half of 2024; the next ME-344 cohort is gated on a 4-month PFS of 20% or higher, and the voruciclib expansion cohort will look at OR.

David Urso emphasized that MEI is moving forward as a standalone oncology company after the Infinity merger ended, and he framed the two programs as the core value drivers for the next few quarters. He highlighted that both assets are built around novel mechanisms and that each is designed to address known resistance mechanisms in existing standards of care. His tone was optimistic but cautious, repeatedly tying future progress to upcoming data readouts.

Jay File said MEI ended the period with $100.7 million in cash, cash equivalents and short-term investments and no debt. He said that level of cash should cover at least the next 12 months and the planned clinical readouts, but he did not provide detailed next-quarter financial guidance. In Q&A, he also noted that R&D was falling as zandelisib and other legacy programs wind down, with about $26 million of the $52.5 million R&D spend tied specifically to zandelisib, which he expects to run out around the October timeframe.

Analysts focused first on runway, asking whether the cash guidance was conservative; management said it was appropriate for the current Phase 1 plans but that Phase 2 timing is too data-dependent to forecast. Questions also centered on what the upcoming voruciclib readout will include, and Richard Ghalie said it will combine safety, PK, biomarker analysis, and potentially recommended Phase 2 dose information. On ME-344, analysts pressed on the 20% four-month PFS gate and historical comparators; management said the threshold was chosen with investigators as a minimum bar and that the result would need to be interpreted in light of the actual patient population enrolled.